Symbols / AIM
AIM Chart
About
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts. The company is also developing Ampligen for potential treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 3.54M |
| Enterprise Value | 3.50M | Income | -15.75M | Sales | 112.00K |
| Book/sh | -2.20 | Cash/sh | 0.84 | Dividend Yield | — |
| Payout | 0.00% | Employees | 21 | IPO | — |
| P/E | — | Forward P/E | -0.24 | PEG | — |
| P/S | 31.60 | P/B | -0.47 | P/C | — |
| EV/EBITDA | -0.24 | EV/Sales | 31.24 | Quick Ratio | 0.60 |
| Current Ratio | 0.64 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -18.16 | EPS next Y | -4.33 | EPS Growth | — |
| Revenue Growth | -25.70% | Earnings | 2025-11-17 16:00 | ROA | -95.42% |
| ROE | — | ROIC | — | Gross Margin | 15.18% |
| Oper. Margin | -94.12% | Profit Margin | 0.00% | Shs Outstand | 3.40M |
| Shs Float | 2.75M | Short Float | 10.30% | Short Ratio | 1.78 |
| Short Interest | — | 52W High | 34.92 | 52W Low | 0.75 |
| Beta | 1.24 | Avg Volume | 1.41M | Volume | 138.59K |
| Target Price | $13.99 | Recom | None | Prev Close | $1.25 |
| Price | $1.04 | Change | -16.80% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$13.99
Mean price target
2. Current target
$1.12
Latest analyst target
3. DCF / Fair value
$-75.02
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.12
Low
$5.99
High
$21.98
Mean
$13.99
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-12-08 | main | Ascendiant Capital | Buy → Buy | $22 |
| 2025-10-03 | main | Ascendiant Capital | Buy → Buy | $24 |
| 2024-12-10 | main | Ascendiant Capital | Buy → Buy | $5 |
| 2024-10-22 | main | Maxim Group | Buy → Buy | $1 |
| 2024-09-03 | main | Ascendiant Capital | Buy → Buy | $5 |
| 2019-10-10 | up | Maxim Group | Hold → Buy | — |
News
RSS: Latest AIM news- EPE Special Opportunities Tightens Free Float With AIM Share Buyback - TipRanks ue, 17 Feb 2026 13
- Experimental drug combo shows survival promise in pancreatic cancer trial - Stock Titan hu, 05 Feb 2026 08
- AIM.AX stock A$0.52 on ASX 17 Feb 2026: near-term trade vs long-term AI upside - Meyka Mon, 16 Feb 2026 23
- London Stock Exchange Sets Out Reforms to AIM Rules - Skadden, Arps, Slate, Meagher & Flom LLP Mon, 08 Dec 2025 08
- Hargreave Hale AIM VCT (LON:HHV) Insider Acquires £636.57 in Stock - MarketBeat Fri, 13 Feb 2026 16
- Is AIM ImmunoTech (AIM) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance hu, 08 Jan 2026 08
- Falcon Oil & Gas Ltd. - Notice of Cancellation of Admission to Trading on AIM - The Manila Times ue, 17 Feb 2026 07
- UK Capital Markets: Shaping the future of AIM – what’s changing now and what’s on the horizon? - www.hoganlovells.com Wed, 26 Nov 2025 08
- AIM offers $1,000 preferred units plus 1,666 stock warrants to holders - Stock Titan hu, 12 Feb 2026 21
- Kalshi Is Taking Aim at Stock Exchanges. Why Not? - Bloomberg.com ue, 25 Nov 2025 08
- AIM ImmunoTech stock plunges after pricing $8 million public offering - Investing.com ue, 29 Jul 2025 07
- Are Medical Stocks Lagging AIM ImmunoTech (AIM) This Year? - Yahoo Finance Wed, 28 Jan 2026 08
- Aimia (TSE:AIM) Stock Price Crosses Above 200 Day Moving Average - Time to Sell? - MarketBeat Fri, 06 Feb 2026 08
- Why Is AIM ImmunoTech Stock Up Today? - TipRanks hu, 05 Feb 2026 08
- Cancer drug developer AIM ImmunoTech seeks $12M from shareholders - Stock Titan Wed, 11 Feb 2026 13
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 2800 | 3444 | — | Stock Award(Grant) at price 1.23 per share. | CHEMEROW DAVID I | Director | — | 2026-02-05 00:00:00 | I |
| 1 | 107 | 824 | — | Purchase at price 7.70 per share. | EQUELS THOMAS K | Chief Executive Officer | — | 2025-06-13 00:00:00 | D |
| 2 | 103 | 9 | — | Purchase at price 0.08 per share. | EQUELS THOMAS K | Chief Executive Officer | — | 2025-06-12 00:00:00 | D |
| 3 | 196851 | 5000 | — | Purchase at price 0.03 per share. | MITCHELL WILLIAM M | Director | — | 2025-04-11 00:00:00 | D |
| 4 | 1968504 | 50000 | — | Purchase at price 0.03 per share. | KELLNER TED D | Director | — | 2025-04-11 00:00:00 | D |
| 5 | 1968504 | 50000 | — | Purchase at price 0.03 per share. | EQUELS THOMAS K | Chief Executive Officer | — | 2025-04-11 00:00:00 | D |
| 6 | 1968504 | 50000 | — | Purchase at price 0.03 per share. | KELLNER TED D | Director | — | 2025-04-11 00:00:00 | D |
| 7 | 500 | 44 | — | Purchase at price 0.09 per share. | RODINO PETER W III | Chief Operating Officer | — | 2025-04-04 00:00:00 | D |
| 8 | 41000 | 2583 | — | Purchase at price 0.06 per share. | EQUELS THOMAS K | Chief Executive Officer | — | 2025-04-04 00:00:00 | D |
| 9 | 44899 | 5208 | — | Stock Award(Grant) at price 0.12 per share. | CHEMEROW DAVID I | Director | — | 2025-03-14 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -15.94M | -28.94M | -18.03M | -13.96M |
| TotalUnusualItems | -551.00K | 218.00K | -1.64M | -4.32M |
| TotalUnusualItemsExcludingGoodwill | -551.00K | 218.00K | -1.64M | -4.32M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -17.32M | -28.96M | -19.45M | -19.13M |
| ReconciledDepreciation | 246.00K | 238.00K | 256.00K | 775.00K |
| ReconciledCostOfRevenue | 31.00K | 42.00K | 0.00 | 850.00K |
| EBITDA | -16.49M | -28.72M | -19.67M | -18.29M |
| EBIT | -16.73M | -28.96M | -19.92M | -19.06M |
| NetInterestIncome | 4.61M | 1.07M | 629.00K | -67.00K |
| InterestExpense | 585.00K | 0.00 | 0.00 | 67.00K |
| InterestIncome | 5.19M | 1.07M | 629.00K | 0.00 |
| NormalizedIncome | -16.77M | -29.18M | -17.80M | -14.81M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -17.32M | -28.96M | -19.45M | -19.13M |
| TotalExpenses | 19.94M | 32.12M | 20.06M | 17.19M |
| TotalOperatingIncomeAsReported | -19.77M | -31.92M | -19.92M | -18.84M |
| DilutedAverageShares | 560.73K | 486.34K | 480.95K | 473.87K |
| BasicAverageShares | 560.73K | 486.34K | 480.95K | 473.87K |
| DilutedEPS | -30.97 | -59.94 | -39.96 | -39.96 |
| BasicEPS | -30.97 | -59.94 | -39.96 | -39.96 |
| DilutedNIAvailtoComStockholders | -17.32M | -28.96M | -19.45M | -19.13M |
| NetIncomeCommonStockholders | -17.32M | -28.96M | -19.45M | -19.13M |
| NetIncome | -17.32M | -28.96M | -19.45M | -19.13M |
| NetIncomeIncludingNoncontrollingInterests | -17.32M | -28.96M | -19.45M | -19.13M |
| NetIncomeContinuousOperations | -17.32M | -28.96M | -19.45M | -19.13M |
| PretaxIncome | -17.32M | -28.96M | -19.45M | -19.13M |
| OtherIncomeExpense | -2.15M | 1.89M | -151.00K | -2.00M |
| OtherNonOperatingIncomeExpenses | -1.60M | 1.67M | 1.49M | 2.32M |
| SpecialIncomeCharges | 0.00 | 18.00K | 3.00K | -4.26M |
| GainOnSaleOfPPE | 0.00 | 18.00K | 3.00K | 216.00K |
| OtherSpecialCharges | 2.70M | |||
| WriteOff | 0.00 | 1.78M | ||
| ImpairmentOfCapitalAssets | 1.78M | |||
| GainOnSaleOfSecurity | -551.00K | 200.00K | -1.64M | -56.00K |
| NetNonOperatingInterestIncomeExpense | 4.61M | 1.07M | 629.00K | -67.00K |
| InterestExpenseNonOperating | 585.00K | 0.00 | 0.00 | 67.00K |
| InterestIncomeNonOperating | 5.19M | 1.07M | 629.00K | 0.00 |
| OperatingIncome | -19.77M | -31.92M | -19.92M | -17.06M |
| OperatingExpense | 19.91M | 32.08M | 20.06M | 16.34M |
| ResearchAndDevelopment | 6.20M | 10.94M | 6.99M | 7.67M |
| SellingGeneralAndAdministration | 13.71M | 21.14M | 13.07M | 8.67M |
| GeneralAndAdministrativeExpense | 13.71M | 21.14M | 13.07M | 8.67M |
| OtherGandA | 13.71M | 21.14M | 13.07M | 8.67M |
| GrossProfit | 139.00K | 160.00K | 141.00K | -715.00K |
| CostOfRevenue | 31.00K | 42.00K | 0.00 | 850.00K |
| TotalRevenue | 170.00K | 202.00K | 141.00K | 135.00K |
| OperatingRevenue | 170.00K | 202.00K | 141.00K | 135.00K |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 655.92K | 491.51K | 481.32K | 480.43K |
| ShareIssued | 655.92K | 491.51K | 481.32K | 480.43K |
| NetDebt | 606.00K | |||
| TotalDebt | 2.94M | 718.00K | 837.00K | 149.00K |
| TangibleBookValue | -3.92M | 7.23M | 35.83M | 54.19M |
| InvestedCapital | 985.00K | 9.54M | 37.77M | 56.16M |
| WorkingCapital | -5.36M | 5.90M | 34.96M | 49.54M |
| NetTangibleAssets | -3.92M | 7.92M | 36.53M | 54.91M |
| CapitalLeaseObligations | 634.00K | 718.00K | 837.00K | 149.00K |
| CommonStockEquity | -1.32M | 9.54M | 37.77M | 56.16M |
| PreferredStockEquity | 689.00K | 696.00K | 715.00K | |
| TotalCapitalization | -1.32M | 10.23M | 38.47M | 56.88M |
| TotalEquityGrossMinorityInterest | -1.32M | 10.23M | 38.47M | 56.88M |
| StockholdersEquity | -1.32M | 10.23M | 38.47M | 56.88M |
| GainsLossesNotAffectingRetainedEarnings | 0.00 | |||
| RetainedEarnings | -426.83M | -409.51M | -380.55M | -361.10M |
| AdditionalPaidInCapital | 425.44M | 419.00M | 418.27M | 417.22M |
| CapitalStock | 66.00K | 738.00K | 744.00K | 763.00K |
| CommonStock | 66.00K | 49.00K | 48.00K | 48.00K |
| PreferredStock | 0.00 | 689.00K | 696.00K | 715.00K |
| TotalLiabilitiesNetMinorityInterest | 9.93M | 9.15M | 2.02M | 820.00K |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 395.00K | 495.00K | 659.00K | 147.00K |
| DerivativeProductLiabilities | 0.00 | 35.00K | ||
| LongTermDebtAndCapitalLeaseObligation | 395.00K | 495.00K | 659.00K | 112.00K |
| LongTermCapitalLeaseObligation | 395.00K | 495.00K | 659.00K | 112.00K |
| CurrentLiabilities | 9.54M | 8.65M | 1.36M | 673.00K |
| CurrentDebtAndCapitalLeaseObligation | 2.55M | 223.00K | 178.00K | 37.00K |
| CurrentCapitalLeaseObligation | 239.00K | 223.00K | 178.00K | 37.00K |
| CurrentDebt | 2.31M | |||
| OtherCurrentBorrowings | 2.31M | |||
| CurrentNotesPayable | 0.00 | |||
| PensionandOtherPostRetirementBenefitPlansCurrent | 1.00K | 414.00K | 1.00K | 1.00K |
| PayablesAndAccruedExpenses | 6.99M | 8.02M | 1.18M | 635.00K |
| CurrentAccruedExpenses | 605.00K | 1.57M | 805.00K | 437.00K |
| InterestPayable | 11.00K | 0.00 | ||
| Payables | 6.38M | 6.44M | 377.00K | 198.00K |
| AccountsPayable | 6.38M | 6.44M | 377.00K | 198.00K |
| TotalAssets | 8.61M | 19.38M | 40.49M | 57.70M |
| TotalNonCurrentAssets | 4.43M | 4.83M | 4.17M | 7.49M |
| OtherNonCurrentAssets | 1.11M | 1.69M | 1.20M | 1.32M |
| InvestmentsAndAdvances | 0.00 | |||
| InvestmentinFinancialAssets | 0.00 | |||
| GoodwillAndOtherIntangibleAssets | 2.59M | 2.31M | 1.94M | 1.97M |
| OtherIntangibleAssets | 2.59M | 2.31M | 1.94M | 1.97M |
| NetPPE | 726.00K | 824.00K | 1.02M | 4.20M |
| AccumulatedDepreciation | -1.36M | -1.32M | -2.04M | -2.21M |
| GrossPPE | 2.08M | 2.15M | 3.06M | 6.40M |
| OtherProperties | 618.00K | 697.00K | 829.00K | 149.00K |
| MachineryFurnitureEquipment | 1.47M | 1.45M | 2.23M | 2.35M |
| Properties | 0.00 | 3.90M | ||
| CurrentAssets | 4.18M | 14.56M | 36.32M | 50.21M |
| OtherCurrentAssets | 199.00K | 302.00K | 455.00K | 304.00K |
| PrepaidAssets | 304.00K | |||
| Receivables | 0.00 | 1.18M | 1.68M | 1.64M |
| OtherReceivables | 1.18M | 1.68M | 1.64M | |
| AccountsReceivable | 1.68M | 1.64M | ||
| CashCashEquivalentsAndShortTermInvestments | 3.98M | 13.07M | 34.19M | 48.27M |
| OtherShortTermInvestments | 2.28M | 7.63M | 7.14M | 16.18M |
| CashAndCashEquivalents | 1.70M | 5.44M | 27.05M | 32.09M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -15.44M | -21.85M | -16.38M | -14.60M |
| RepaymentOfDebt | -251.00K | 0.00 | 0.00 | -4.85M |
| IssuanceOfDebt | 2.50M | 0.00 | ||
| IssuanceOfCapitalStock | 892.00K | 485.00K | 80.00K | 13.04M |
| CapitalExpenditure | -556.00K | -585.00K | -271.00K | -633.00K |
| EndCashPosition | 1.70M | 5.44M | 27.05M | 32.09M |
| BeginningCashPosition | 5.44M | 27.05M | 32.09M | 38.50M |
| ChangesInCash | -3.74M | -21.61M | -5.04M | -6.41M |
| FinancingCashFlow | 6.44M | 485.00K | 80.00K | 8.19M |
| CashFlowFromContinuingFinancingActivities | 6.44M | 485.00K | 80.00K | 8.19M |
| ProceedsFromStockOptionExercised | 3.30M | 0.00 | ||
| NetCommonStockIssuance | 892.00K | 485.00K | 80.00K | 13.04M |
| CommonStockIssuance | 892.00K | 485.00K | 80.00K | 13.04M |
| NetIssuancePaymentsOfDebt | 2.25M | 0.00 | 0.00 | -4.85M |
| NetLongTermDebtIssuance | 2.25M | 0.00 | 0.00 | -4.85M |
| LongTermDebtPayments | -251.00K | 0.00 | 0.00 | -4.85M |
| LongTermDebtIssuance | 2.50M | 0.00 | ||
| InvestingCashFlow | 4.71M | -832.00K | 10.99M | -631.00K |
| CashFlowFromContinuingInvestingActivities | 4.71M | -832.00K | 10.99M | -631.00K |
| NetInvestmentPurchaseAndSale | 5.26M | -294.00K | 7.36M | -243.00K |
| SaleOfInvestment | 5.62M | 1.30M | 10.08M | 22.29M |
| PurchaseOfInvestment | -361.00K | -1.59M | -2.72M | -22.54M |
| NetIntangiblesPurchaseAndSale | -538.00K | -585.00K | -185.00K | -592.00K |
| PurchaseOfIntangibles | -538.00K | -585.00K | -185.00K | -592.00K |
| NetPPEPurchaseAndSale | -18.00K | 47.00K | 3.81M | 204.00K |
| SaleOfPPE | 0.00 | 47.00K | 3.90M | 245.00K |
| PurchaseOfPPE | -18.00K | 0.00 | -86.00K | -41.00K |
| OperatingCashFlow | -14.89M | -21.27M | -16.11M | -13.96M |
| CashFlowFromContinuingOperatingActivities | -14.89M | -21.27M | -16.11M | -13.96M |
| ChangeInWorkingCapital | 296.00K | 7.13M | 966.00K | 895.00K |
| ChangeInOtherCurrentLiabilities | -309.00K | -274.00K | 688.00K | -30.00K |
| ChangeInOtherCurrentAssets | 576.00K | -486.00K | -83.00K | 0.00 |
| ChangeInPayablesAndAccruedExpense | -1.26M | 7.25M | 547.00K | -189.00K |
| ChangeInAccruedExpense | -1.20M | 1.18M | 368.00K | -4.00K |
| ChangeInInterestPayable | 0.00 | |||
| ChangeInPayable | -60.00K | 6.07M | 179.00K | -185.00K |
| ChangeInAccountPayable | -60.00K | 6.07M | 179.00K | -185.00K |
| ChangeInPrepaidAssets | 103.00K | 153.00K | -151.00K | 1.63M |
| ChangeInReceivables | 1.18M | 492.00K | -35.00K | -517.00K |
| ChangesInAccountReceivables | 0.00 | 34.00K | ||
| OtherNonCashItems | 605.00K | 287.00K | -680.00K | 2.78M |
| StockBasedCompensation | 686.00K | 243.00K | 954.00K | 1.57M |
| ProvisionandWriteOffofAssets | 0.00 | |||
| AssetImpairmentCharge | 48.00K | 14.00K | 0.00 | 1.78M |
| DeferredTax | 0.00 | 197.00K | -2.32M | |
| DeferredIncomeTax | 0.00 | 197.00K | -2.32M | |
| DepreciationAmortizationDepletion | 246.00K | 238.00K | 256.00K | 775.00K |
| DepreciationAndAmortization | 246.00K | 238.00K | 256.00K | 775.00K |
| AmortizationCashFlow | 209.00K | 199.00K | 218.00K | 116.00K |
| AmortizationOfIntangibles | 209.00K | 199.00K | 218.00K | 116.00K |
| Depreciation | 37.00K | 39.00K | 38.00K | 659.00K |
| OperatingGainsLosses | 551.00K | -218.00K | 1.64M | -314.00K |
| GainLossOnInvestmentSecurities | 551.00K | -200.00K | 1.64M | -98.00K |
| GainLossOnSaleOfPPE | 0.00 | -18.00K | 0.00 | -216.00K |
| NetIncomeFromContinuingOperations | -17.32M | -28.96M | -19.45M | -19.13M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for AIM
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|